Insider trade

Officer sold ~$126K of CORT shares in the open market

Traded Oct 2, 2026 · Filed Oct 6, 2026

~$126K
Approx. value · 1,100 sh @ $114.52: 11K
Holds after · shares reported: +5.0%
stock since the trade · S&P 500 +0.7%, $116.23 → $122.03 on Oct 5

Why it stands out

Corcept Therapeutics's President, Oncology sold $126K of Corcept Therapeutics shares. The filing says it was made under a pre-arranged trading plan.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

Dates, kept separate

Transaction date: Oct 2, 2026
Reporting period: Not applicable
Filed with the SEC: Oct 6, 2026

Officer$100K–$500KPre-arranged plan referenced

Context

Classification

open market sale

Code S — open-market or private sale

Absolute commitment

~$125,973

Shares × reported transaction price

Timing vs results

65 days after results of Jul 29, 2026

Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results

Price at the time

Closed at $116.23 on Oct 2, 2026, 262% above its 52-week low and 6% below its high, after a 4% drop over the previous 30 trading days

52-week range $32.15 (Mar 13, 2026) to $123.57 (Aug 25, 2026), 92% of the way up, from 250 adjusted closes. 30 trading days earlier: $121.05 on Aug 20, 2026. Describes the past only, not a forecast

Planned / mechanical clue

Footnote references a pre-arranged trading plan (Rule 10b5-1)

Only flagged when a footnote says so; never inferred

Source receipt

Record ID: 0001193125-26-414688
Filed / recorded: Oct 6, 2026, 3:58 AM UTC
Added to OQRO: Oct 6, 2026, 7:14 PM UTC
Parser: form4-xml-v2
Data quality: Verified: identifiers matched exactly
Issuer: CORCEPT THERAPEUTICS INC
Issuer CIK: 1088856
Ticker: CORT
Reporting person: Roberto Wandenkolk Vieira
Relationship: Officer
Officer title: President, Oncology
Security: Common Stock
Table: Non-derivative (Table I)
Transaction date: Oct 2, 2026
Transaction code: S
Shares / units: 1,100
Price per share: $114.52
Acquired / disposed: Disposed (D)
Shares owned after: 11,179
Ownership form: Direct
Amendment: No

Footnotes from the filing

This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on June 17, 2026, prior to the Reporting Person being appointed an officer of the Issuer, which was in effect at the time of this transaction.
Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $114.03 to $114.90 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
Includes 179 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 396 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026, 634 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026 and 138 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.

Around the same time

Roberto Wandenkolk VieiraPresident, Oncology

Filed yesterday

8,333Shares · @ $21.63

Traded Oct 2 · filed 4 days later

Derivative exercise or conversion — not an open-market buy.

More Official record

Roberto Wandenkolk Vieira (President, Oncology) sold ~$241K of Corcept Therapeutics

Scheduled in advanceFiled yesterday

Roberto Wandenkolk Vieira (President, Oncology) sold ~$600K of Corcept Therapeutics

Scheduled in advanceFiled yesterday